Ress Life Investments A/S
Ress Life Investments A/S publishes Net Asset Value (NAV)
Ress Life Investments A/S publishes Net Asset Value (NAV)
Ress Life Investments
Nybrogade 12
DK-1203 Copenhagen K
Denmark
CVR nr. 33593163
www.resslifeinvestments.com
To: Nasdaq Copenhagen
Date: 15 December 2025
Corporate Announcement 38/2025
Ress Life Investments A/S publishes Net Asset Value (NAV).
Ress Life Investments A/S publishes the Net Asset Value (NAV) per share as of 28 November 2025.
NAV per share in USD: 2606.23
The performance during November is 0.37% in USD. The year-to-date net performance is 0.42% in USD.
Assets under management (AUM) are 218.6 million USD.
The NAV per share in EUR is published on the website of Nasdaq Copenhagen under the section AIF Companies and Funds, where the bid and ask prices are published. The daily NAV in EUR is calculated as the most recently published NAV in USD divided by the European Central Bank’s EUR/USD reference rate on the relevant day.
Questions related to this announcement can be made to the company's AIF-manager, Resscapital AB.
Contact person:
Gustaf Hagerud
gustaf.hagerud@resscapital.com
Tel + 46 73 660 72 42
Note: The terms for subscription of shares, minimum subscription amount and redemption of shares are provided in the Articles of Association, Information Brochure and in the Key Information Document available on the Company's website, www.resslifeinvestments.com.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ITHAX Acquisition Corp III15.12.2025 22:01:00 CET | Press release
ITHAX Acquisition Corp III Announces Closing of $230 Million Initial Public Offering
Theon International PLC15.12.2025 20:59:47 CET | Press release
THEON Announces Results of the Rights Issue
Digitalist Group Oyj15.12.2025 19:08:39 CET | Press release
Digitalist Group Oyj - Managers' Transactions
Solvay S.A.15.12.2025 17:45:00 CET | Press release
Participation notification by UBS Group AG
Ipsen Pharma15.12.2025 17:30:00 CET | Press release
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom